Active MPN Research
With many clinical trials in progress, as well as clinicians and laboratory scientists around the world researching MPNs, our understanding of these diseases continues to grow. New research on the causes and treatment of MPNs is constantly being published. Here you can find links to the latest MPN research publications.
- Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications.
- Successive development of ischemic stroke and hemorrhagic stroke in a patient with essential thrombocythemia: a case report.
- Low-density lipoprotein (LDL) and the risk of thrombotic events in essential thrombocythemia and polycythemia vera.
- Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation.
- JAK3 Is Expressed in the Nucleus of Malignant T Cells in Cutaneous T Cell Lymphoma (CTCL).
- The Current Status of Screening for Essential Thrombocythemia and Polycythemia Vera in Clinical Practice-Report from a Single Institution.
- [A Case of Ascending Colon Cancer with Essential Thrombocythemia].
- miR-135a inhibits airway inflammatory response in asthmatic mice via regulating JAK/STAT signaling pathway.
- Higher serum uric acid is associated with higher risks of thrombosis and death in patients with primary myelofibrosis.
- Opioids drive breast cancer metastasis through the δ-opioid receptor and oncogenic STAT3.
- Differential in vitro interactions of the Janus kinase inhibitor ruxolitinib with human SLC drug transporters.
- Secondary erythrocytosis due to hemoglobin San Diego.
- Portal Vein Thrombosis Secondary to Occult Polycythemia Vera.
- The Dangers of Immediately Performing a Sensitive and Specific Investigation versus the Dangers of Delaying It: A Cautionary Case of Hodgkin’s Lymphoma.
- Risk of hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients with myeloproliferative neoplasms treated with ruxolitinib.